HVTN 706/ HPX3002 Mosaico |
HIV Vaccine |
III |
October 2019 |
United States of America, Argentina, Italy, Mexico, Peru, Poland, Spain |
Men |
Ad26.Mos4.HIV, gp140 |
Ongoing |
PV1/PrEPVacc |
HIV Vaccine, PrEP |
IIb |
January 2020 |
Uganda, South Africa, United Republic of Tanzania, Mozambique |
|
DNA , MVA, Protein |
Ongoing |
HVTN 124/ PDPHV-201401 |
HIV Vaccine |
I |
March 2018 |
United States of America |
Men, Women |
gp120 (A,B,C,A/E)/GLA-SE, env (A,B,C,A/E)/gag (C)/GLA-SE |
Ongoing |
HVTN 122/gp145 C.6980 |
HIV Vaccine |
I |
December 2017 |
United States of America |
Men, Women |
gp145 C.6980 |
Ongoing |
HVTN 115/ EnvSeq-1 and CH505 |
HIV Vaccine |
I |
August 2017 |
United States of America |
Men, Women |
CH505TF |
Ongoing |
HVTN 705/ HPX2008/ CR108263: The Imbokodo Study |
HIV Vaccine |
IIb |
November 2017 |
Malawi, Mozambique, South Africa, Zambia, Zimbabwe |
Women |
Ad26.Mos.HIV, gp140 |
Ongoing |
HPX2003/HVTN118/IPCAVD012/ASCENT |
HIV Vaccine |
I/II |
March 2017 |
United States of America |
|
Ad26.Mos.HIV, gp140 |
Ongoing |
HVTN 117/HPX2004/IPCAVD011/TRAVERSE |
HIV Vaccine |
I/II |
June 2016 |
United States of America, Rwanda |
Women, Men |
Ad26.Mos.HIV, gp140 |
Ongoing |
Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers |
HIV Vaccine |
I |
October 2013 |
United States of America |
Women, Men |
Ad4 |
Ongoing |
Study of Immune Responses Induced by a HIV Vaccine (RV328) |
HIV Vaccine |
II |
July 2014 |
Thailand |
Women, Men |
AIDSVAX |
Ongoing |
HVTN 112 |
HIV Vaccine |
I |
March 2016 |
United States of America |
Women, Men |
rVSV |
Ongoing |
HVTN 110 |
HIV Vaccine |
I |
March 2015 |
United States of America |
Women, Men |
Ad4, AIDSVAX, gp120 |
Ongoing |
HVTN 107 |
HIV Vaccine |
I/II |
March 2017 |
South Africa, Mozambique, Zimbabwe |
Women, Men |
ALVAC, gp120 |
Ongoing |
HVTN 108 |
HIV Vaccine |
I/II |
December 2016 |
United States of America, South Africa |
Women, Men |
DNA plasmid, gp120 |
Ongoing |
HVTN 702 |
HIV Vaccine |
III, IIb |
October 2016 |
South Africa |
Men, Women |
ALVAC, gp120 |
Ongoing |
HVTN 111 |
HIV Vaccine |
I |
May 2016 |
South Africa, United Republic of Tanzania, Zambia |
Women, Men |
gp120 |
Ongoing |
HVTN 106 |
HIV Vaccine |
I |
January 2015 |
United States of America, Switzerland |
Women, Men |
DNA , MVA |
Ongoing |
HIV-V-A004/IPCAVD 009 (APPROACH) |
HIV Vaccine |
I/II |
December 2014 |
United States of America, Rwanda, South Africa, Thailand, Uganda |
Women, Men |
Ad26.Mos.HIV, gp140, MVA |
Ongoing |
HVTN 114 |
HIV Vaccine |
I |
February 2017 |
United States of America, Peru |
|
AIDSVAX, gp120, MVA |
Ongoing |
RV 306 |
HIV Vaccine |
II |
September 2013 |
Thailand |
Men, Women |
AIDSVAX, ALVAC |
Ongoing |